An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19).
Identifieur interne : 001563 ( Main/Corpus ); précédent : 001562; suivant : 001564An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19).
Auteurs : Saibal Das ; Subhrojyoti Bhowmick ; Sayali Tiwari ; Sukanta SenSource :
- Clinical drug investigation [ 1179-1918 ] ; 2020.
English descriptors
- KwdEn :
- Animals (MeSH), Anti-Bacterial Agents (therapeutic use), Azithromycin (therapeutic use), COVID-19 (MeSH), Clinical Trials as Topic (MeSH), Coronavirus Infections (drug therapy), Drug Therapy, Combination (MeSH), Humans (MeSH), Hydroxychloroquine (adverse effects), Hydroxychloroquine (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (drug therapy).
- MESH :
- chemical , adverse effects : Hydroxychloroquine.
- chemical , therapeutic use : Anti-Bacterial Agents, Azithromycin, Hydroxychloroquine.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Animals, COVID-19, Clinical Trials as Topic, Drug Therapy, Combination, Humans, Pandemics.
Abstract
BACKGROUND AND OBJECTIVE
The world is currently experiencing the Coronavirus Disease-19 (COVID-19) pandemic. There is no approved drug for the definitive treatment of the disease. Various drugs are being tried for the treatment of COVID-19, including hydroxychloroquine (HCQ). This study was performed to systematically review the therapeutic role of HCQ in COVID-19 from the available literature.
METHODS
PubMed, Embase, ClinicalTrials.gov, ICTRP (WHO), Cochrane Library databases, and two pre-print servers (medRxiv.org and Research Square) were searched for clinical studies that evaluated the therapeutic role of HCQ on COVID-19 until 10 May 2020. The available studies were critically analyzed and the data were extracted.
RESULTS
A total of 663 articles were screened and 12 clinical studies (seven peer-reviewed and published studies and five non-peer-reviewed studies from pre-print servers) with a total sample size of 3543 patients were included. Some of the clinical studies demonstrated good virological and clinical outcomes with HCQ alone or in combination with azithromycin in COVID-19 patients, although the studies had major methodological limitations. Some of the other studies showed negative results with HCQ therapy along with the risk of adverse reactions.
CONCLUSION
The results of efficacy and safety of HCQ in COVID-19, as obtained from the clinical studies, are not satisfactory, although many of these studies had major methodological limitations. Stronger evidence from well-designed robust randomized clinical trials is required before conclusively determining the role of HCQ in the treatment of COVID-19. Clinical prudence is required in advocating HCQ as a therapeutic armamentarium in COVID-19.
DOI: 10.1007/s40261-020-00927-1
PubMed: 32468425
PubMed Central: PMC7255448
Links to Exploration step
pubmed:32468425Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19).</title><author><name sortKey="Das, Saibal" sort="Das, Saibal" uniqKey="Das S" first="Saibal" last="Das">Saibal Das</name><affiliation><nlm:affiliation>Department of Clinical Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, 605 006, India.</nlm:affiliation></affiliation></author><author><name sortKey="Bhowmick, Subhrojyoti" sort="Bhowmick, Subhrojyoti" uniqKey="Bhowmick S" first="Subhrojyoti" last="Bhowmick">Subhrojyoti Bhowmick</name><affiliation><nlm:affiliation>Department of Pharmacology, KPC Medical College and Hospital, Kolkata, 700 032, India. drsubhro@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Tiwari, Sayali" sort="Tiwari, Sayali" uniqKey="Tiwari S" first="Sayali" last="Tiwari">Sayali Tiwari</name><affiliation><nlm:affiliation>Department of Community Medicine, Lokmanya Tilak Municipal Medical College and General Hospital, Mumbai, 400 022, India.</nlm:affiliation></affiliation></author><author><name sortKey="Sen, Sukanta" sort="Sen, Sukanta" uniqKey="Sen S" first="Sukanta" last="Sen">Sukanta Sen</name><affiliation><nlm:affiliation>Department of Pharmacology, ICARE Institute of Medical Sciences and Research, Haldia, 721 645, India.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32468425</idno><idno type="pmid">32468425</idno><idno type="doi">10.1007/s40261-020-00927-1</idno><idno type="pmc">PMC7255448</idno><idno type="wicri:Area/Main/Corpus">001563</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001563</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19).</title><author><name sortKey="Das, Saibal" sort="Das, Saibal" uniqKey="Das S" first="Saibal" last="Das">Saibal Das</name><affiliation><nlm:affiliation>Department of Clinical Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, 605 006, India.</nlm:affiliation></affiliation></author><author><name sortKey="Bhowmick, Subhrojyoti" sort="Bhowmick, Subhrojyoti" uniqKey="Bhowmick S" first="Subhrojyoti" last="Bhowmick">Subhrojyoti Bhowmick</name><affiliation><nlm:affiliation>Department of Pharmacology, KPC Medical College and Hospital, Kolkata, 700 032, India. drsubhro@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Tiwari, Sayali" sort="Tiwari, Sayali" uniqKey="Tiwari S" first="Sayali" last="Tiwari">Sayali Tiwari</name><affiliation><nlm:affiliation>Department of Community Medicine, Lokmanya Tilak Municipal Medical College and General Hospital, Mumbai, 400 022, India.</nlm:affiliation></affiliation></author><author><name sortKey="Sen, Sukanta" sort="Sen, Sukanta" uniqKey="Sen S" first="Sukanta" last="Sen">Sukanta Sen</name><affiliation><nlm:affiliation>Department of Pharmacology, ICARE Institute of Medical Sciences and Research, Haldia, 721 645, India.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical drug investigation</title><idno type="eISSN">1179-1918</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Azithromycin (therapeutic use)</term><term>COVID-19 (MeSH)</term><term>Clinical Trials as Topic (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Drug Therapy, Combination (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (adverse effects)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Azithromycin</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>COVID-19</term><term>Clinical Trials as Topic</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Pandemics</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND AND OBJECTIVE</b></p><p>The world is currently experiencing the Coronavirus Disease-19 (COVID-19) pandemic. There is no approved drug for the definitive treatment of the disease. Various drugs are being tried for the treatment of COVID-19, including hydroxychloroquine (HCQ). This study was performed to systematically review the therapeutic role of HCQ in COVID-19 from the available literature.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>PubMed, Embase, ClinicalTrials.gov, ICTRP (WHO), Cochrane Library databases, and two pre-print servers (medRxiv.org and Research Square) were searched for clinical studies that evaluated the therapeutic role of HCQ on COVID-19 until 10 May 2020. The available studies were critically analyzed and the data were extracted.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>A total of 663 articles were screened and 12 clinical studies (seven peer-reviewed and published studies and five non-peer-reviewed studies from pre-print servers) with a total sample size of 3543 patients were included. Some of the clinical studies demonstrated good virological and clinical outcomes with HCQ alone or in combination with azithromycin in COVID-19 patients, although the studies had major methodological limitations. Some of the other studies showed negative results with HCQ therapy along with the risk of adverse reactions.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>The results of efficacy and safety of HCQ in COVID-19, as obtained from the clinical studies, are not satisfactory, although many of these studies had major methodological limitations. Stronger evidence from well-designed robust randomized clinical trials is required before conclusively determining the role of HCQ in the treatment of COVID-19. Clinical prudence is required in advocating HCQ as a therapeutic armamentarium in COVID-19.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32468425</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1918</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical drug investigation</Title><ISOAbbreviation>Clin Drug Investig</ISOAbbreviation></Journal><ArticleTitle>An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19).</ArticleTitle><Pagination><MedlinePgn>591-601</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40261-020-00927-1</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="OBJECTIVE">The world is currently experiencing the Coronavirus Disease-19 (COVID-19) pandemic. There is no approved drug for the definitive treatment of the disease. Various drugs are being tried for the treatment of COVID-19, including hydroxychloroquine (HCQ). This study was performed to systematically review the therapeutic role of HCQ in COVID-19 from the available literature.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, Embase, ClinicalTrials.gov, ICTRP (WHO), Cochrane Library databases, and two pre-print servers (medRxiv.org and Research Square) were searched for clinical studies that evaluated the therapeutic role of HCQ on COVID-19 until 10 May 2020. The available studies were critically analyzed and the data were extracted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 663 articles were screened and 12 clinical studies (seven peer-reviewed and published studies and five non-peer-reviewed studies from pre-print servers) with a total sample size of 3543 patients were included. Some of the clinical studies demonstrated good virological and clinical outcomes with HCQ alone or in combination with azithromycin in COVID-19 patients, although the studies had major methodological limitations. Some of the other studies showed negative results with HCQ therapy along with the risk of adverse reactions.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results of efficacy and safety of HCQ in COVID-19, as obtained from the clinical studies, are not satisfactory, although many of these studies had major methodological limitations. Stronger evidence from well-designed robust randomized clinical trials is required before conclusively determining the role of HCQ in the treatment of COVID-19. Clinical prudence is required in advocating HCQ as a therapeutic armamentarium in COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Saibal</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, 605 006, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhowmick</LastName><ForeName>Subhrojyoti</ForeName><Initials>S</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-2599-7532</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, KPC Medical College and Hospital, Kolkata, 700 032, India. drsubhro@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiwari</LastName><ForeName>Sayali</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, Lokmanya Tilak Municipal Medical College and General Hospital, Mumbai, 400 022, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sen</LastName><ForeName>Sukanta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, ICARE Institute of Medical Sciences and Research, Haldia, 721 645, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Clin Drug Investig</MedlineTA><NlmUniqueID>9504817</NlmUniqueID><ISSNLinking>1173-2563</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32468425</ArticleId><ArticleId IdType="doi">10.1007/s40261-020-00927-1</ArticleId><ArticleId IdType="pii">10.1007/s40261-020-00927-1</ArticleId><ArticleId IdType="pmc">PMC7255448</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Countries where Coronavirus has spread—Worldometer. https://www.worldometers.info/coronavirus/countries-where-coronavirus-has-spread/ . Accessed 10 May 2020</Citation></Reference><Reference><Citation>Sahu KK, Mishra AK, Lal A. COVID-2019: update on epidemiology, disease spread and management. Monaldi Arch Chest Dis Arch Monaldi Mal Torace. 2020. https://doi.org/10.4081/monaldi.2020.1292 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/monaldi.2020.1292</ArticleId></ArticleIdList></Reference><Reference><Citation>Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105938 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105938</ArticleId><ArticleId IdType="pubmed">32179150</ArticleId><ArticleId IdType="pmcid">7102624</ArticleId></ArticleIdList></Reference><Reference><Citation>Golden EB, Cho H-Y, Hofman FM, Louie SG, Schönthal AH, Chen TC. Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus. 2015;38(3):E12. https://doi.org/10.3171/2014.12.FOCUS14748 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2014.12.FOCUS14748</ArticleId><ArticleId IdType="pubmed">25727221</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722–7. https://doi.org/10.1016/s1473-3099(03)00806-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(03)00806-5</ArticleId><ArticleId IdType="pubmed">14592603</ArticleId><ArticleId IdType="pmcid">7128816</ArticleId></ArticleIdList></Reference><Reference><Citation>Fantini J, Di Scala C, Chahinian H, Yahi N. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105960 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105960</ArticleId><ArticleId IdType="pubmed">32405156</ArticleId><ArticleId IdType="pmcid">7219429</ArticleId></ArticleIdList></Reference><Reference><Citation>Comparison of random and site directed mutation effects on the efficacy between lead SARS-CoV2 anti-protease drugs. Indinavir and Hydroxychloroquine. 2020; https://doi.org/10.21203/rs.3.rs-22082/v1</Citation></Reference><Reference><Citation>Yao X, Ye F, Zhang M, et al. In Vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis Off Publ Infect Dis Soc Am. 2020. https://doi.org/10.1093/cid/ciaa237 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa237</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1):1–4. https://doi.org/10.1038/s41421-020-0156-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-0156-0</ArticleId><ArticleId IdType="pubmed">6952422</ArticleId><ArticleId IdType="pmcid">6952422</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreani J, Le Bideau M, Duflot I, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog. 2020. https://doi.org/10.1016/j.micpath.2020.104228 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2020.104228</ArticleId><ArticleId IdType="pubmed">32344177</ArticleId><ArticleId IdType="pmcid">7182748</ArticleId></ArticleIdList></Reference><Reference><Citation>Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857–e208857208857. https://doi.org/10.1001/jamanetworkopen.2020.8857 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.8857</ArticleId><ArticleId IdType="pubmed">32339248</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastick KA, Okafor EC, Wang F, et al. Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis. 2020. https://doi.org/10.1093/ofid/ofaa130 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa130</ArticleId><ArticleId IdType="pubmed">32363212</ArticleId><ArticleId IdType="pmcid">7184359</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020;369:m1432. https://doi.org/10.1136/bmj.m1432 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1432</ArticleId><ArticleId IdType="pubmed">32269046</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus: we are now receiving patients suffering from chloroquine poisoning, says Lagos govt, NCDC cautions Nigerians. https://tribuneonlineng.com/coronavirus-we-are-now-receiving-patients-suffering-from-chloroquine-poisoning-says-lagos-govt-ncdc-cautions-nigerians/ . Accessed 15 Apr 2020</Citation></Reference><Reference><Citation>Man fatally poisons himself while self-medicating for coronavirus, doctor says—the New York times. https://www.nytimes.com/2020/03/24/us/chloroquine-poisoning-coronavirus.html . Accessed 15 Apr 2020</Citation></Reference><Reference><Citation>Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.1096 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1096</ArticleId><ArticleId IdType="pubmed">32219357</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Altman DG, Gøtzsche PC, et al. The cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011. https://doi.org/10.1136/bmj.d5928 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pubmed">22096256</ArticleId><ArticleId IdType="pmcid">3196245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ottawa Hospital Research Institute. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp . Accessed 8 May 2020</Citation></Reference><Reference><Citation>Gautret P, Lagier J-C, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020. https://doi.org/10.1016/j.tmaid.2020.101663 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2020.101663</ArticleId><ArticleId IdType="pubmed">32525075</ArticleId><ArticleId IdType="pmcid">7194574</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial. MedRxiv. 2020. https://doi.org/10.1101/2020.03.16.20037135 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.16.20037135</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Jun LD, Chen Jun LD. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ Med Sci. 2020. https://doi.org/10.3785/j.issn.1008-9292.2020.03.03 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3785/j.issn.1008-9292.2020.03.03</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Médecine Mal Infect. 2020. https://doi.org/10.1016/j.medmal.2020.03.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medmal.2020.03.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2012410 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2012410</ArticleId><ArticleId IdType="pubmed">32379955</ArticleId><ArticleId IdType="pmcid">7224609</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.1834 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1834</ArticleId><ArticleId IdType="pubmed">32356863</ArticleId><ArticleId IdType="pmcid">7195692</ArticleId></ArticleIdList></Reference><Reference><Citation>Million M, Lagier J-C, Gautret P, et al. Full-length title: early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille. France Travel Med Infect Dis. 2020. https://doi.org/10.1016/j.tmaid.2020.101738 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2020.101738</ArticleId><ArticleId IdType="pubmed">32387409</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. 2020. https://doi.org/10.1101/2020.03.22.20040758 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.22.20040758</ArticleId><ArticleId IdType="pubmed">32511657</ArticleId><ArticleId IdType="pmcid">7277008</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahevas M, Tran V-T, Roumier M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv. 2020. https://doi.org/10.1101/2020.04.10.20060699 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.10.20060699</ArticleId></ArticleIdList></Reference><Reference><Citation>Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. 2020. https://doi.org/10.1101/2020.04.16.20065920 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.16.20065920</ArticleId><ArticleId IdType="pubmed">32511622</ArticleId><ArticleId IdType="pmcid">7276049</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv. 2020. https://doi.org/10.1101/2020.04.10.20060558 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.10.20060558</ArticleId><ArticleId IdType="pubmed">32511650</ArticleId><ArticleId IdType="pmcid">7277006</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramireddy A, Chugh HS, Reinier K, et al. Experience with hydroxychloroquine and azithromycin in the COVID-19 pandemic: implications for QT interval monitoring. medRxiv. 2020. https://doi.org/10.1101/2020.04.22.20075671 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.22.20075671</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105949 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105949</ArticleId><ArticleId IdType="pubmed">32205204</ArticleId><ArticleId IdType="pmcid">7102549</ArticleId></ArticleIdList></Reference><Reference><Citation>Biot C, Daher W, Chavain N, et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem. 2006;49(9):2845–9. https://doi.org/10.1021/jm0601856 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm0601856</ArticleId><ArticleId IdType="pubmed">16640347</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiryaev SA, Mesci P, Pinto A, et al. Repurposing of the anti-malaria drug chloroquine for Zika Virus treatment and prophylaxis. Sci Rep. 2017;7(1):15771. https://doi.org/10.1038/s41598-017-15467-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-15467-6</ArticleId><ArticleId IdType="pubmed">29150641</ArticleId><ArticleId IdType="pmcid">5694003</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowall SD, Bosworth A, Watson R, et al. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. J Gen Virol. 2015;96(12):3484–92. https://doi.org/10.1099/jgv.0.000309 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000309</ArticleId><ArticleId IdType="pubmed">26459826</ArticleId><ArticleId IdType="pmcid">5410110</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzarano D, Safronetz D, Prescott J, Marzi A, Feldmann F, Feldmann H. Lack of protection against ebola virus from chloroquine in mice and hamsters. Emerg Infect Dis. 2015;21(6):1065–7. https://doi.org/10.3201/eid2106.150176 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2106.150176</ArticleId><ArticleId IdType="pubmed">25988934</ArticleId><ArticleId IdType="pmcid">4451918</ArticleId></ArticleIdList></Reference><Reference><Citation>Roques P, Thiberville S-D, Dupuis-Maguiraga L, et al. Paradoxical effect of chloroquine treatment in enhancing Chikungunya virus infection. Viruses. 2018. https://doi.org/10.3390/v10050268 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10050268</ArticleId><ArticleId IdType="pubmed">29772762</ArticleId><ArticleId IdType="pmcid">5977261</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L-F, Lin Y-S, Huang N-C, et al. Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res. 2015;35(3):143–56. https://doi.org/10.1089/jir.2014.0038 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2014.0038</ArticleId></ArticleIdList></Reference><Reference><Citation>Borges MC, Castro LA, de Fonseca BAL. Chloroquine use improves dengue-related symptoms. Mem Inst Oswaldo Cruz. 2013;108(5):596–9. https://doi.org/10.1590/s0074-02762013000500010 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s0074-02762013000500010</ArticleId><ArticleId IdType="pubmed">23903975</ArticleId><ArticleId IdType="pmcid">3970591</ArticleId></ArticleIdList></Reference><Reference><Citation>Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis. 2011;11(9):677–83. https://doi.org/10.1016/S1473-3099(11)70065-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(11)70065-2</ArticleId><ArticleId IdType="pubmed">21550310</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafsson LL, Walker O, Alván G, et al. Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol. 1983;15(4):471–9. https://doi.org/10.1111/j.1365-2125.1983.tb01532.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1983.tb01532.x</ArticleId><ArticleId IdType="pubmed">6849784</ArticleId><ArticleId IdType="pmcid">1427807</ArticleId></ArticleIdList></Reference><Reference><Citation>Guastalegname M, Vallone A. Could chloroquine/hydroxychloroquine be harmful in coronavirus disease 2019 (COVID-19) treatment? Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa321 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa321</ArticleId><ArticleId IdType="pubmed">32211771</ArticleId><ArticleId IdType="pmcid">7184345</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kofahi M, Jacobson P, Boulware DR, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.1874 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1874</ArticleId><ArticleId IdType="pubmed">32344449</ArticleId><ArticleId IdType="pmcid">7267462</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber K, Hom C, Chao CP, Shapiro D, Ash J. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J. 2009;7:9. https://doi.org/10.1186/1546-0096-7-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1546-0096-7-9</ArticleId><ArticleId IdType="pubmed">19439078</ArticleId><ArticleId IdType="pmcid">2690583</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapp JL, Alqarawi W, MacIntyre CJ, et al. Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: a statement from the Canadian Heart Rhythm society. Can J Cardiol. 2020. https://doi.org/10.1016/j.cjca.2020.04.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2020.04.003</ArticleId><ArticleId IdType="pubmed">32553606</ArticleId><ArticleId IdType="pmcid">7293761</ArticleId></ArticleIdList></Reference><Reference><Citation>Asli R, Abdullah MS, Chong PL, et al. Case report: right bundle brunch block and QTc prolongation in a patient with novel coronavirus disease (COVID-19) treated with hydroxychloroquine. Am J Trop Med Hyg. 2020. https://doi.org/10.4269/ajtmh.20-0376 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.20-0376</ArticleId><ArticleId IdType="pubmed">32500854</ArticleId><ArticleId IdType="pmcid">7263524</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang D, Saleh M, Gabriels J, et al. Inpatient use Of Ambulatory Telemetry Monitors for COVID-19 patients treated with hydroxychloroquine and/or azithromycin. J Am Coll Cardiol. 2020. https://doi.org/10.1016/j.jacc.2020.04.032 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.04.032</ArticleId><ArticleId IdType="pubmed">32330546</ArticleId><ArticleId IdType="pmcid">7262575</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr. 2020;14(3):241–6. https://doi.org/10.1016/j.dsx.2020.03.011 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.03.011</ArticleId><ArticleId IdType="pubmed">32247211</ArticleId><ArticleId IdType="pmcid">7102587</ArticleId></ArticleIdList></Reference><Reference><Citation>Gbinigie K, Frie K. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. BJGP Open. 2020. https://doi.org/10.3399/bjgpopen20X101069 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgpopen20X101069</ArticleId><ArticleId IdType="pubmed">32398343</ArticleId></ArticleIdList></Reference><Reference><Citation>McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis. 2020;7(4):105. https://doi.org/10.1093/ofid/ofaa105 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa105</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin EJ, Harrington DP, Hogan JW, Gatsonis C, Baden LR, Hamel MB. The urgency of care during the Covid-19 pandemic—learning as we go. N Engl J Med. 2020. https://doi.org/10.1056/NEJMe2015903 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe2015903</ArticleId><ArticleId IdType="pubmed">32558483</ArticleId><ArticleId IdType="pmcid">7269012</ArticleId></ArticleIdList></Reference><Reference><Citation>Taccone FS, Gorham J, Vincent J-L. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med. 2020. https://doi.org/10.1016/S2213-2600(20)30172-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30172-7</ArticleId><ArticleId IdType="pubmed">32304640</ArticleId><ArticleId IdType="pmcid">7159849</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020. https://doi.org/10.1001/jama.2020.6019 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6019</ArticleId><ArticleId IdType="pubmed">32282022</ArticleId></ArticleIdList></Reference><Reference><Citation>AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf</Citation></Reference><Reference><Citation>Shah S, Das S, Jain A, Misra DP, Negi VS. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19). Int J Rheum Dis. 2020. https://doi.org/10.1111/1756-185X.13842 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.13842</ArticleId><ArticleId IdType="pubmed">32281213</ArticleId><ArticleId IdType="pmcid">7262257</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet Infect Dis. 2020. https://doi.org/10.1016/S1473-3099(20)30313-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30313-3</ArticleId><ArticleId IdType="pubmed">32311324</ArticleId><ArticleId IdType="pmcid">7164849</ArticleId></ArticleIdList></Reference><Reference><Citation>D’Cruz M. The ICMR bulletin on targeted hydroxychloroquine prophylaxis for Covid-19: need to interpret with caution. Indian J Med Ethics. 2020;5(2):100–2.</Citation><ArticleIdList><ArticleId IdType="doi">10.20529/IJME.2020.040</ArticleId></ArticleIdList></Reference><Reference><Citation>La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2020. https://doi.org/10.1007/s10096-020-03913-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-020-03913-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim AHJ, Sparks JA, Liew JW, et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med. 2020. https://doi.org/10.7326/M20-1223 .</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-1223</ArticleId><ArticleId IdType="pubmed">32539440</ArticleId><ArticleId IdType="pmcid">7273461</ArticleId></ArticleIdList></Reference><Reference><Citation>Search of: Hydroxychloroquine | COVID 19 - List Results - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?cond=COVID+19&term=Hydroxychloroquine&cntry=&state=&city=&dist =. Accessed 5 May 2020</Citation></Reference><Reference><Citation>WHO | Welcome to the WHO ICTRP. In: WHO. https://www.who.int/ictrp/en/ . Accessed 5 May 2020</Citation></Reference><Reference><Citation>Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ. Chloroquine for SARS-CoV-2: implications of its unique pharmacokinetic and safety properties. Clin Pharmacokinet. 2020. https://doi.org/10.1007/s40262-020-00891-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-020-00891-1</ArticleId><ArticleId IdType="pubmed">32306288</ArticleId><ArticleId IdType="pmcid">7165255</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001563 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001563 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32468425
|texte= An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32468425" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |